A Prospective Cohort of Children With HIV Infection

• Status: Recruiting
• Trial end date: 2030-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate clinical and immunological outcome of children treated with HAART.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
• Collaborator: Khon Kaen University
• Treatments: Didanosine; Efavirenz; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Ritonavir; Saquinavir; Stavudine; Zidovudine

Criteria

Inclusion Criteria:

• Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center

• Children who fulfil criteria to start HAART according to the ATC program

• Children who are switched to second regimen or salvage therapy

• Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)

• Children with HIV infection who are not on antiretroviral therapy

• Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form

Exclusion Criteria:

• Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.